NCT01159496已完成1 期
A Randomized Investigator And Subject-Blind, Sponsor Open, Placebo Controlled Phase 1 Study To Characterize The Safety, Tolerability, And Pharmacokinetics Of Ascending Multiple Doses Of PF-05212377 (SAM-760) Administered Orally To Healthy Young And Elderly Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Adverse events (spontaneous and solicited).
研究概览
简要总结
This is a multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of PF-05212377 (SAM-760) administered orally once a day for 14 days to healthy young adults and healthy elderly subjects. The study will be conducted under double-blind conditions (neither the investigator nor the subject will know if he/she has received PF-05212377 or a placebo). The Sponsor will know if the subject has received active treatment or a placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Inclusion Criteria for young healthy population: Healthy male and/or female subjects of non-child bearing potential (WONCBP) between the ages of 18 and 55 years, inclusive. (Healthy is defined as no clinically relevant abnormalities identified at screening by a detailed medical history, full physical examination, including blood pressure and heart rate measurement, 12-lead ECG, neurological examination and clinical laboratory tests.)
- •Inclusion Criteria for elderly population: Healthy male and/or female subjects of non-child bearing potential between the ages of 65 and 85 years, inclusive. Subjects must be in reasonably good health as determined by the investigator based on a detailed medical history, full physical examination (including blood pressure and pulse rate measurement), 12-lead ECG and clinical laboratory tests. Subjects with mild, chronic, stable disease (eg, controlled hypertension, non-insulin dependent diabetes, osteoarthritis) may be enrolled if deemed medically prudent by the investigator.
排除标准
- •Presence or history of any disorder that may prevent the successful completion of the study.
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- •A score of greater than or equal to 20 on the Beck Depression Inventory and/or a response of 1, 2, or 3 to the question related to suicide.
- •History of seizure disorder and/or severe head trauma (other than a single childhood febrile seizure).
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, dermatologic, muscular or allergic disease or disorder (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- •Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the study treatment.
- •Acute disease state (eg, nausea, vomiting, fever, or diarrhea) within 7 days before study Day
- •History of drug abuse within 1 year before study Day 1 or a positive urine drug screen.
- •Admitted alcohol abuse or history of alcohol use that may interfere with the subject's ability to comply with the protocol requirements.
- •Consumption of more than 14 drinks/week for females or 21 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
- •Subjects who smoke more than 10 cigarettes per day.
- •Pregnant or nursing females; females of childbearing potential.
- •Males who are unwilling to abstain from sexual intercourse or use a condom with all child-bearing potential women for the duration of the study.
研究组 & 干预措施
Active
Experimental
干预措施: PF-05212377 (SAM-760) (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Adverse events (spontaneous and solicited).
时间窗: 0-24days
Change from baseline in vital signs.
时间窗: 0-24 days
Change from baseline in triplicate ECGs.
时间窗: 0-24 days
Clinical safety laboratory endpoints, including a complete blood count, reticulocytes and a full chemistry panel, including electrolytes, hepatic transaminases, and urinalysis, with microscopic analysis if dipstick analysis is positive.
时间窗: 0-24 days
Physical examinations and neurological examinations
时间窗: 0-24 days
次要结局
- Pharmacokinetics in young adults (Plasma concentration of PF-05212377 over time (eg, AUC, Cmax, Tmax, t1/2).(0-21 days)
- Pharmacokinetics in elderly subjects (Plasma concentration of PF-05212377 over time (eg, AUC, Cmax, Tmax, t1/2).(0-21 days)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy SubjectsOverweight or ObesityNCT06762600Fujian Shengdi Pharmaceutical Co., Ltd.103
招募中
1 期
A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383CoughNCT06092983Jiangsu Hansoh Pharmaceutical Co., Ltd.48
已完成
1 期
The PK/PD Study of SHR7280 Tablets in Healthy Subjects.Healthy SubjectsNCT04554043Jiangsu HengRui Medicine Co., Ltd.118
Unknown
1 期
A Study of TG103 in Subjects With Type 2 DiabetesType 2 DiabetesNCT04790006CSPC ZhongQi Pharmaceutical Technology Co., Ltd.54
已完成
1 期
A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.Diabetes Mellitus Type 2NCT00682097Hoffmann-La Roche55